Marcos Aurelio Gomes Da Silva*
Federal University of Juiz De Fora, Brazil
*Corresponding Author: Marcos Aurelio Gomes Da Silva, Federal University of Juiz De Fora, Brazil.
Received: March 24, 2020; Published: May 07, 2020
Favipiravir is an antiviral drug that selectively inhibits the RNAdependent RNA polymerase of influenza virus. It is phosphoribosylated by cellular enzymes to its active form, favipiravir-ribofuranosyl- 5'-triphosphate (RTP). Favipiravir is active against a broad range of influenza viruses, including A(H1N1)pdm09, A(H5N1) and the recently emerged A(H7N9) avian virus. It also inhibits influenza strains resistant to current antiviral drugs, and shows a synergistic effect in combination with oseltamivir, thereby expanding influenza treatment options. Recently, T-705 has been shown to give 100% protection against aerosol Ebola virus E718 infection in immune-deficient mice as well as inhibiting Ebola virus infection in cell culture.
Citation: Marcos Aurelio Gomes Da Silva. “Favipiravir and Coronavirus” Acta Scientific Pharmaceutical Sciences 4.6 (2020): 02.
Copyright: © 2020 Marcos Aurelio Gomes Da Silva. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.